secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K/A
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001520138-22-000392
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 9.01, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements
--------------------------------------------------------------------------------

- 82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.
- NE3107 significantly reduced TNF-alpha; improvements in cognition correlated with TNF reduction (R=0.70, p=0.0077).
- Phase 3 AD trial (NCT04669028) half enrolled; topline data expected mid-2023, subject to DSMB review.
- Phase 2 Parkinson's trial (NCT05083260) enrolling; data readout by end of 2022; early efficacy signal detected.
- Phase 2b BIV201 trial for ascites delayed by COVID; data readout anticipated mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/0001520138-22-000392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/bivi-20220907_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001520138-22-000392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer